Celcuity (NASDAQ:CELC) Director David Dalvey Sells 25,000 Shares

Celcuity, Inc. (NASDAQ:CELC) Director David Dalvey sold 25,000 shares of the company’s stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $140.68, for a total transaction of $3,517,000.00. Following the sale, the director directly owned 65,000 shares in the company, valued at approximately $9,144,200. This trade represents a 27.78% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Celcuity Price Performance

NASDAQ CELC opened at $139.44 on Thursday. The company has a market cap of $6.74 billion, a PE ratio of -36.79 and a beta of 0.09. Celcuity, Inc. has a 52 week low of $9.51 and a 52 week high of $151.02. The company has a quick ratio of 10.55, a current ratio of 10.55 and a debt-to-equity ratio of 3.20. The firm’s 50-day simple moving average is $115.96 and its two-hundred day simple moving average is $103.90.

Celcuity (NASDAQ:CELC) last released its quarterly earnings data on Wednesday, March 25th. The company reported ($0.97) EPS for the quarter, beating the consensus estimate of ($1.06) by $0.09. Research analysts predict that Celcuity, Inc. will post -3.87 earnings per share for the current year.

Key Celcuity News

Here are the key news stories impacting Celcuity this week:

• Positive Sentiment: Phase III clinical success — Celcuity’s PI3K/mTOR inhibitor gedatolisib showed a survival benefit and outperformed a Novartis comparator in a Phase III metastatic PIK3CA+ breast cancer study, providing a major commercial/clinical catalyst if confirmed and advancing the company’s drug?development thesis. Gedatolisib Improves Survival Gedatolisib Beats Novartis
• Positive Sentiment: Analyst support — Guggenheim reiterated a Buy rating on CELC, which can reinforce investor confidence and provide buying support following the clinical readout. Guggenheim Keeps Their Buy Rating on Celcuity (CELC)
• Neutral Sentiment: HC Wainwright model updates — the firm trimmed near?term quarterly EPS forecasts (Q1–Q3 and Q2 2026 nudged lower) but raised Q4 2026 and materially lifted FY2027–FY2030 long?range estimates (FY2030 raised sharply to $16.69). This is a mixed signal: short?term profitability remains negative, but the research note increases long?term upside assumptions that investors may price in. (Research note summary)
• Neutral Sentiment: Market commentary on valuation — coverage questioning whether CELC is still worth buying after a large run?up has appeared, which can temper momentum as some investors reassess risk/reward. Is It Too Late To Consider Celcuity (CELC) After A 13x One Year Surge?
• Negative Sentiment: Insider sales under 10b5?1 plans — Director Richard Buller sold 9,000 shares (~$1.26M) and Director David Dalvey sold 25,000 shares (~$3.52M) at ~ $140.5 on May 4; both transactions were disclosed on Form 4s and executed under pre?arranged 10b5?1 plans. Planned insider selling can create short?term selling pressure or signal liquidity events even though 10b5?1 plans reduce information asymmetry. Buller Form 4 Dalvey Form 4

Wall Street Analysts Forecast Growth

Several research firms have commented on CELC. Wall Street Zen downgraded shares of Celcuity from a “hold” rating to a “sell” rating in a report on Saturday, April 25th. Needham & Company LLC increased their price target on shares of Celcuity from $122.00 to $157.00 and gave the stock a “buy” rating in a report on Monday. Wolfe Research reissued an “outperform” rating and issued a $110.00 price target on shares of Celcuity in a report on Thursday, March 12th. Citizens Jmp increased their price target on shares of Celcuity from $150.00 to $160.00 and gave the stock a “market outperform” rating in a report on Monday. Finally, Citigroup reissued an “outperform” rating on shares of Celcuity in a report on Monday. Ten equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $134.50.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Ogorek Anthony Joseph NY ADV increased its position in shares of Celcuity by 19.7% in the fourth quarter. Ogorek Anthony Joseph NY ADV now owns 662 shares of the company’s stock worth $66,000 after purchasing an additional 109 shares during the last quarter. US Bancorp DE increased its position in shares of Celcuity by 25.4% in the third quarter. US Bancorp DE now owns 706 shares of the company’s stock worth $35,000 after purchasing an additional 143 shares during the last quarter. Intech Investment Management LLC increased its position in shares of Celcuity by 1.4% in the fourth quarter. Intech Investment Management LLC now owns 12,983 shares of the company’s stock worth $1,295,000 after purchasing an additional 183 shares during the last quarter. Aristides Capital LLC increased its position in shares of Celcuity by 2.0% in the fourth quarter. Aristides Capital LLC now owns 15,303 shares of the company’s stock worth $1,526,000 after purchasing an additional 303 shares during the last quarter. Finally, EverSource Wealth Advisors LLC increased its position in shares of Celcuity by 1,329.2% in the fourth quarter. EverSource Wealth Advisors LLC now owns 343 shares of the company’s stock worth $34,000 after purchasing an additional 319 shares during the last quarter. 63.33% of the stock is currently owned by institutional investors.

Celcuity Company Profile

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.